BI
SRPT icon

Binnacle Investments’s Sarepta Therapeutics SRPT Stock Holding History

Binnacle Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$39 Buy
+2
New +$36 ﹤0.01% 934

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Binnacle Investments's SRPT Position: Q3 2025 in Review

Binnacle Investments opened a new position in Sarepta Therapeutics (SRPT) in Q3 2025: 2 shares worth $39. The stake represents ﹤0.01% of the portfolio and ranks #934 among its holdings.

319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Binnacle Investments held 2 shares of Sarepta Therapeutics worth $39 as of Q3 2025.
  • Sarepta Therapeutics was a new Binnacle Investments position in Q3 2025.
  • Sarepta Therapeutics made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #934 holding.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.